Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2015. The document serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, in accordance with DTR 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share acquisition details.
- Share Price: 1364.28 pence per Share.
- Transaction Type: Acquisition of Ordinary Shares via dividend re-investment.
- Dividend Payment Date: July 9, 2015.
Material Changes
The filing reports specific share acquisitions by the following individuals following the dividend re-investment:
- Sir Andrew Witty (Director): Acquired 5,070 Ordinary Shares.
- Lady C Witty (Connected Person): Acquired 2,213 Ordinary Shares.
- Mr I W Whyte (Connected Person): Acquired 390 Ordinary Shares.
No material changes to financial performance or operational status are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of insider transactions only.
Investor Verification Points
- Verify the total number of shares acquired by directors and connected persons (7,673 shares total).
- Confirm the share price of 1364.28 pence used for the dividend re-investment.
- Review the dividend payment date of July 9, 2015, to align with the transaction timing.